Option chain shows key data for Society Pass's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Society Pass.

Society Pass (NASDAQ:SOPA) Stock, Option Chain

Society Pass

Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with visionary entrepreneurs, the company meets the growing demand for better services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food and grocery deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Merchant Point of Sale (merchant POS). The company generates the majority of its revenue from the Digital marketing segment.

Nike Inc.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AENT

BATL

BNZI

GNFT

KOPN

KSPI

LFLY

RZLV

SOPA

SVMH

TNON

TOMZ

VEEA

XCUR

Why Nike Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

movers image

ADXN

ATXG

BLDP

CNET

CTNT

GLPG

GSX Techedu Inc. American Depositary Shares

GOTU

ILAG

MAPS

SMFL

TANH

TCOM

TRIB

TUYA

VVPR

Why Trip.com Group Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket

Intraday Update

APLD

ATPC

AVAH

CMAX

CRWD

DOGZ

EMBC

FTEL

KARO

LGCB

LPSN

MEDS

MEIP

MIRA

MNSO

NCPL

NUKK

NWGL

PRTG

PSIG

RYAAY

SAVA

SERV

SLNA

SLRX

SNOA

TELL

TKNO

VIRI

Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Society Pass Inc

Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) has outperformed the market over the past 10 years by 8.15% on an annualized basis producing an average annual return of 19.35%. Currently, Arthur J. Gallagher has a market capitalization of $68.92 billion. 
Buying $100 In AJG: If an investor had bought $100 of AJG stock 10 years ago, it would be worth $591.91 today based on a price of $275.89 for AJG at the time of writing.
<h3>Arthur J. Gallagher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735854309_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Arthur J. Gallagher 10 Years Ago Would Be Worth This Much Today

Investors dumped a popular long-dated Treasury ETF at a record pace in December, fleeing the bond market as surging yields and fiscal uncertainty cast a shadow ahead of President-elect Donald Trump's return <a href="https://www.benzinga.com/topic/donald-trump">to the White House.</a>
The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>), the largest Treasury-focused exchange-traded fund with $50 billion in assets under management, recorded $5.5 billion in outflows last month. 
This marks the fund's largest single-month outflows in its history, surpassing the $4 billion withdrawn during the pandemic-driven turmoil in March 2020.
On the performance front, the fund tumbled by 7.1% in December, recording the worst drop since September 2023. 
<h3 class="wp-block-heading">Chart: TLT ETF Witnessed Record Monthly Outflows In December</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="541" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02151804/image-8-1024x541.png" alt="" class="wp-image-715974" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02151804/image-8-1024x541.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02151804/image-8-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02151804/image-8-768x406.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02151804/image-8-1536x812.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02151804/image-8.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">Yields Soar As Trump Policies Ignite Inflation Risks</h3>
Yields on 30-year Treasury bonds climbed sharply, gaining more than 40 basis points in December to close the year at 4.80%. That's the highest level in over a year, driven by concerns about rising inflation and shifting monetary policy.
The Federal Reserve, which delivered a 25-basis-point interest rate cut in December, sounded hawkish in its accompanying guidance.
Officials signaled fewer rate cuts in 2025 than markets had expected and raised inflation forecasts to reflect upcoming administration policies.
&#8220;The&nbsp;Bond&nbsp;Vigilantes are sending a loud warning message,&#8221; said Ed Yardeni, president of Yardeni Research, in a recent note. 
&#8220;They aren&#8217;t convinced Donald Trump, the new sheriff coming to town, will maintain fiscal law and order any better than the old sheriff. They are also losing their confidence in Jerome Powell, the deputy in charge of monetary law and order,&#8221; he added.
In a recent report, Bravos Research highlighted that&nbsp;the 10-year&nbsp;Treasury&nbsp;yield&nbsp;rocketed from 3.6% in September to 4.6% in late December, implying a 25% increase in just 100 trading sessions.
&#8220;Moves like this are rare and have massive implications for the stock market,&#8221; the Bravos Research Team wrote. 
<h3 class="wp-block-heading">Trump's Policies Add To Market Jitters</h3>
Investor anxiety over Trump's incoming administration added another layer of complexity to the bond market.
Trump has floated the idea of scrapping the federal debt ceiling, a controversial move that could enable unchecked government borrowing and stoke inflationary pressures.
Such a policy would effectively remove a key restraint on federal deficits, raising alarm among bond investors already bracing for fiscal expansion.
"There's now more bad reasons for the rise in yields," Yardeni stated. 
As the expert highlighted, while stronger-than-expected economic data in the second half of 2024 initially pushed bond yields higher, the recent decline in the Citigroup Economic Surprise Index has shifted focus to structural concerns, such as persistent inflation risks and growing deficits.
Investors are also bracing for potential trade turbulence, as Trump has pledged to impose a universal 10% tariff and hike tariffs on Chinese imports to 60%. These measures, if enacted, could exacerbate inflationary pressures and add fuel to the bond market&#8217;s recent turmoil.
<h3 class="wp-block-heading">Treasury Department Breach Highlights New Risks</h3>
Compounding the challenges in December, the U.S. Treasury Department confirmed it was the target of a Chinese state-sponsored cyberattack. 
Hackers compromised a third-party vendor, BeyondTrust, and gained access to unclassified documents, according to a <a href="https://legacy.www.documentcloud.org/documents/25472740-letter-to-chairman-brown-and-ranking-member-scott/">letter</a> sent to lawmakers.
The major breach allowed hackers to override security protocols and access Treasury workstations via a stolen key. 
The Treasury Department said it became aware of the attack on Dec. 8 and is working with the FBI and the Cybersecurity and Infrastructure Security Agency (CISA) to assess the damage.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42768507/china-slaps-export-restrictions-on-dozens-of-us-companies-boeing-lockheed-martin-general-dynamics-raytheon-affected">China&#8217;s Export Crackdown Hits Boeing, Lockheed Martin And More</a></li>
</ul>
Photo: Shutterstock

Government

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

ETFs

iShares Trust Barclays 20+ Year Treasury Bond Fund

Investors Dump Long-Dated Treasury ETF At Record Pace Ahead Of Trump's White House Return

The company has rescheduled its conference call from the previously announced date of Thursday, January 9, 2025 in observance of the declared national day of mourning for former President Jimmy Carter.

Constellation Brands Reschedules Q3 Financial Results Release To January 10, 2025

Russian gas exports reportedly stopped running through Soviet-era Ukrainian pipelines on Wednesday after Ukraine refused to renew <a href="https://www.benzinga.com/news/econ-s/25/01/42769181/natural-gas-prices-surge-as-arctic-blast-freezes-us-3-stocks-on-the-move">a transit agreement.</a>
The Details: Russia's gas firm Gazprom said the gas stopped at 0500 GMT after Ukraine refused to renew the transit agreement in a widely anticipated move.  
Reuters reported that Ukrainian President Volodymyr Zelenskyy wrote on Telegram that the end of Russian natural gas flows through Ukraine was &#8220;one of Moscow&#8217;s biggest defeats.&#8221;&nbsp;
Zelenskyy also encouraged allies to supply more gas to Europe to fill the gap left by the end of the Russian supply.&nbsp;
&#8220;The more there is on the market from Europe&#8217;s real partners, the faster we will overcome the last negative consequences of European energy dependence on Russia,&#8221; he wrote.
Read Next: <a href="https://www.benzinga.com/news/global/24/12/42743937/natural-gas-prices-spike-as-bone-chilling-arctic-blast-approaches">Natural Gas Prices Spike As &#8216;Bone-Chilling&#8217; Arctic Blast Approaches</a>
Shares of U.S.-based liquified natural gas exporters, including Devon Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) and Cheniere Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>), are up Thursday as LNG exports to Europe are expected to rise in 2025. 
"Cheniere's LNG has been a vital part of the European response to Russia's war in Ukraine and has shown how security of supply, in the form of reliability of production and flexibility of delivery, are vastly important for this moment, and for the decades to come," Corey Grindal, COO of Cheniere Energy said in a 2023<a href="https://www.lng2023.org/news/cheniere-key-contributor-european-energy-security"> interview</a>.&nbsp;
"Cheniere produced about 11% of all LNG worldwide in 2022 and more than 70% of Cheniere's LNG was exported to Europe, by Cheniere or our customers," Grindal added.&nbsp;
The European Commission released a statement stating that the EU had anticipated and prepared for the stoppage of Russian gas flows.&nbsp;
‘&#8221;The European gas infrastructure is flexible enough to provide gas of non-Russian origin,&#8221; a spokesperson for the commission said. &#8220;It has been reinforced with significant new LNG (liquefied natural gas) import capacities since 2022.&#8221;
According to Reuters, Hungary will continue to receive Russian gas through the TurkStream pipeline and the last remaining European buyers of Russian gas, Slovakia and Austria, have arranged other supplies. &nbsp;
The Slovakian government said on Tuesday that there is no danger of a gas shortage and its state-owned gas firm SPP has gas supply contracts with large international suppliers including BP PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>), Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) and Shell PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>). 
Investors can monitor the broader energy sector through the SPDR Select Energy Sector Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) which tracks the S&amp;P Energy Select Sector Index, composed of 22 companies that primarily develop and produce crude oil and natural gas. 
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/42768507/china-slaps-export-restrictions-on-dozens-of-us-companies-boeing-lockheed-martin-general-dynamics-raytheon-affected">China&#8217;s Export Crackdown Hits Boeing, Lockheed Martin And More&nbsp;</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

Eurozone

Commodities

Global

SHEL

Russian Natural Gas Delivery To Europe Halted: US-Listed LNG Stocks Gain As Exports Set To Increase In 2025

Act III has agreed to a customary standstill, voting commitment, and related provisions in connection with the Cooperation Agreement.

BJRI

BJ's Restaurants Enters Cooperation Agreement With Act III Holdings, LLC And Various Affiliates Of Ronald M. Shaich

President-elect Donald Trump said the deadly New Orleans attack was a good reason to crack down on immigration even though the attacker, identified by authorities as Shamsud-Din Jabbar, was born and raised in the United States and <a href="https://www.benzinga.com/news/25/01/42772041/fbi-confirms-lone-suspect-in-new-orleans-attack-vegas-probe-ongoing">served in the U.S. Army</a>.
Building on an earlier <a href="https://truthsocial.com/@realDonaldTrump/posts/113757022203490348">Truth Social rant</a> shortly after the terrorist attack in which Trump called the U.S. a laughing stock and blamed the "open borders" of the Biden administration, he <a href="https://truthsocial.com/@realDonaldTrump/posts/113757022203490348">let loose again on Thursday</a>, referring to "the outside and inside violent SCUM that has infiltrated all aspects of our government, and our Nation itself."
Trump used the New Orleans attack that killed at least 14 people and injured dozens more to bash the FBI, the Department of Justice and other agencies. He called on the CIA to get involved even though the agency deals with foreign rather than domestic issues.
"The USA is breaking down &#8211; A violent erosion of Safety, National Security, and Democracy is taking place all across our Nation. Only strength and powerful leadership will stop it," Trump wrote.
President Joe Biden, who called the attack "despicable," expressed sympathy for the victims' families and the city of New Orleans.
"The situation is very fluid," said Biden, <a href="https://www.washingtonpost.com/nation/2025/01/01/new-orleans-vehicle-crowd-bourbon-street/">according</a> to the Washington Post. "The investigation is continuing to be active, and no one should jump to conclusions." Biden acknowledged that the perpetrator was an American citizen born in Texas who served in the U.S. Army and was likely influenced by the Islamic State.
"The FBI also reported to me that mere hours before the attack, he posted videos on social media indicating that [he] was inspired by ISIS," Biden said.
A top FBI official detailed the series of videos posted by the Bourbon Street attacker in which he claimed to have joined ISIS, <a href="https://www.nola.com/news/crime_police/bourbon-street-attack-isis/article_fd9d20e4-c927-11ef-8203-63f6eb3110b4.html">reported</a> nola.com.  
 &#8220;In the first video, Jabbar explains he originally planned to harm his family and friends, but was concerned the news headlines would not focus on the quote, &#8216;war between the believers and the disbelievers,&#8217; end quote,&#8221; Christopher Raia, deputy assistant director of the FBI&#8217;s Counterterrorism Division, reportedly said at a press conference.
Raia also <a href="https://www.nola.com/news/crime_police/bourbon-street-attack-isis/article_fd9d20e4-c927-11ef-8203-63f6eb3110b4.html">said</a> the FBI believes that Jabbar acted alone and that, at this point, no links have been uncovered between the New Orleans attack and the Tesla Cybertruck explosion in Las Vegas. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/sports/25/01/42771050/new-orleans-beefs-up-security-ahead-of-sugar-bowl-tickets-plummet-to-25-as-fans-leave-town">New Orleans Beefs Up Security Ahead Of Sugar Bowl, Tickets Plummet To $25 As Fans Leave Town</a></li>
</ul>
Photo via Shutterstock.

Politics

Media

Trump Calls FBI, DOJ 'Incompetent And Corrupt,' US A 'Laughing Stock' — Biden Calls NOLA Attack 'Despicable,' Expresses Sympathy For Victims' Families

Automatic Data Processing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>) has outperformed the market over the past 15 years by 2.19% on an annualized basis producing an average annual return of 13.66%. Currently, Automatic Data Processing has a market capitalization of $118.02 billion. 
Buying $100 In ADP: If an investor had bought $100 of ADP stock 15 years ago, it would be worth $681.85 today based on a price of $289.65 for ADP at the time of writing.
<h3>Automatic Data Processing's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735853410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Automatic Data Processing Stock In The Last 15 Years

That includes $2.23 billion domestically and $3.23 billion internationally. Disney is the first studio to surpass $5 billion worldwide since 2019 and has been No. 1 for 8 of the past 9 consecutive years globally.

Walt Disney Studios Says It Topped 2024 Global Box Office, Bringing In $5.46B Around The World

Guerisoli and Lamb are existing directors of the Company.

Management

PNTG

Pennant Group Appoints Brent Guerisoli As Chairman And Scott Lamb As Lead Independent Director, Each Effective January 1, 2025

This change follows the recent announcement of the stock market closure on the original scheduled date. The Company's quarterly earnings press release will cross the wire after market close on January 10, 2025.

Earnings

WDFC

WD-40  Reschedules Q1 FY25 Earnings Conference Call To January 10, 2025

Joe Fisher has been appointed to the role of Chief Investment Officer in addition to his roles as President and Chief Financial Officer.

UDR Promotes Mike Lacy To COO; Plans To Initiate An Executive Search Process To Recruit  New CFO

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 10 years by 6.38% on an annualized basis producing an average annual return of 17.58%. Currently, UnitedHealth Group has a market capitalization of $464.29 billion. 
Buying $100 In UNH: If an investor had bought $100 of UNH stock 10 years ago, it would be worth $510.02 today based on a price of $504.51 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735852508_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 10 Years

Lifecore Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) announced its Q2 earnings on Thursday, January 2, 2025 at 04:05 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Lifecore Biomedical beat estimated earnings by 19.0%, reporting an EPS of $-0.25 versus an estimate of $-0.31.
Revenue was up $2.41 million from the same period last year.
<h3>Overview of Past Earnings</h3>
The company missed on EPS by $0.07 in the last quarter, resulting in a 14.000000000000002% increase share price change the following day.

To track all earnings releases for Lifecore Biomedical <a href="https://www.benzinga.com/quote/LFCR/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LFCR

Lifecore Biomedical Earnings Report: Q2 Overview

Resources Connection (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGP#NASDAQ">RGP</a>) reported its Q2 earnings results on Thursday, January 2, 2025 at 04:10 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Resources Connection beat estimated earnings by 0.18%, reporting an EPS of $0.18 versus an estimate of $0.0.
Revenue was down $17.51 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company missed on EPS by $0.03 in the last quarter, resulting in a 12.0% drop share price change the following day.
Here's a look at Resources Connection's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.03</td>
<td>0.07</td>
<td>0.05</td>
<td>0.18</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0</td>
<td>0.28</td>
<td>0.17</td>
<td>0.28</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>137.92M</td>
<td>140.60M</td>
<td>152.77M</td>
<td>161.94M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>136.94M</td>
<td>148.20M</td>
<td>151.31M</td>
<td>163.13M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Resources Connection <a href="https://www.benzinga.com/quote/RGP/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Resources Connection Q2 Earnings

WIIM

CHEK

Check-Cap shares are trading higher after the company announced it was granted European Patent Number EP4087488 titled "RADIATION CAPSULE FOR BOWEL DISEASE IMAGING AND LOCALIZE DRUG DELIVERY".

Resources Connection (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGP#NASDAQ">RGP</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of undefined by Infinity percent. The company reported quarterly sales of $145.60 million which beat the analyst consensus estimate of $137.02 million by 6.26 percent. This is a 10.74 percent decrease over sales of $163.13 million the same period last year.

Earnings Beats

Resources Connection Q2 2025 Adj EPS $0.18 Beats $0 Estimate, Sales $145.60M Beat $137.02M Estimate

SPSC

Sps Commerce Announces It Has Reached An Agreement To Acquire CARBON6 Technologies, Inc; Terms Not Disclosed

Yum! Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>), the parent company of <a href="https://www.benzinga.com/general/restaurants">KFC, Pizza Hut and Taco Bell</a>, is nearing a potential <a href="https://www.benzinga.com/topic/golden-cross">Golden Cross</a>, a bullish technical indicator that could signal a turnaround for the stock.
While the stock is down 3.9% in the past month, recent upgrades and growth initiatives could bring renewed momentum to the stock.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="629" height="492" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02083745/Screenshot-2025-01-02-at-5.51.03-PM.png" alt="" class="wp-image-715166" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02083745/Screenshot-2025-01-02-at-5.51.03-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02083745/Screenshot-2025-01-02-at-5.51.03-PM-300x235.png 300w" sizes="(max-width: 629px) 100vw, 629px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010225&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">YUM Stock Chart Has Mixed Signals, As Golden Cross Looms</h2>
At $134.16, YUM stock sits just below key moving averages, creating a mixed technical picture:
<ul>
<li>Eight-day SMA: A bullish signal at $133.81, indicating slight upward momentum.</li>
<li>20-day, 50-day and 200-day SMAs: All hovering above the current price, signaling bearish conditions.</li>
<li>MACD: At a negative 0.55, it reinforces a bearish sentiment.</li>
<li>RSI: A neutral 46.54 suggests neither overbought nor oversold conditions.</li>
</ul>
However, the eight-day SMA edging above the price hints at brewing buying pressure, while a looming Golden Cross—where the 50-day SMA crosses above the 200-day SMA—could ignite bullish enthusiasm.
Read Also: <a href="https://www.benzinga.com/24/12/42679687/mcdonalds-evangelion-collaboration-advert-catches-elon-musks-eye-heres-what-the-techno-king-shared">McDonald&#8217;s Evangelion Collaboration Advert Catches Elon Musk&#8217;s Eye. Here&#8217;s What The Techno King Shared</a>
<h2 class="wp-block-heading">YUM Stock Investors: What To Watch</h2>
For YUM stock investors, the potential Golden Cross could serve as a signal to ride Yum's recovery wave, particularly with Argus projecting long-term earnings growth of 10%. If momentum continues, YUM stock might finally break past its resistance levels and begin its climb toward the $155 target.
While bears remain skeptical, citing mixed short-term signals, Yum's blend of technical potential and fundamental optimism is worth watching. 
Will the Golden Cross be the catalyst Yum needs? Investors might not have to wait much longer to find out.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42702291/fast-food-robots-smaller-stores-wholesale-clubs-retail-trends-for-2025">Fast-Food Robots, Smaller Stores, Wholesale Clubs: 2025 Retail Trends To Watch</a></li>
</ul>
Photo: Shutterstock

Technicals

Restaurants

Signals

General

Yum! Brands Nears Golden Cross As Investors Look For Bullish Signs

Lifecore Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.29) by 13.79 percent. The company reported quarterly sales of $32.60 million which beat the analyst consensus estimate of $29.75 million by 9.59 percent. This is a 8.13 percent increase over sales of $30.15 million the same period last year.

Lifecore Biomedical Q2 2025 GAAP EPS $(0.25) Beats $(0.29) Estimate, Sales $32.60M Beat $29.75M Estimate

PINE

Alpine Income Property Trust Acquires Lowe's Home Improvement For $22.5M

Warning: SOPA is at high risk of performing badly

Society Pass regains compliance with Nasdaq minimum closing bid price rule

In a report released yesterday, Allen Klee from Maxim Group maintained a Hold rating on Society Pass (SOPA – Research Report). The company's shares...

Maxim Group Remains a Hold on Society Pass (SOPA)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Making millions through the stock market is only possible in a few ways. Investors need one of these three things: 



<ul><li>Massive sums of capital to begin with</li>



<li>Decades of time and more modest sums of capital</li>



<li>More modest sums of capital and a combination of risk and luck</li>
</ul>We will be talking about the latter today: seven stocks you can buy for $2 that can 10X by 2025. The standard caveat applies here, which says investors should only spend what they are willing to lose. 



Investing in sub-$2 stocks is very risky. Direct the majority of your capital toward more stable, conservative approaches. Direct much less capital to these riskier stocks that will require a combination of risk and luck.



All of the stocks discussed below cost less than $2 per share meaning $1,000 will get you at least 500 shares. Those 500 or more shares have the potential to appreciate in value above $10,000 by 2025.



<h2>Reliance Global (RELI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/insurance-300x169.jpg" alt="Man in suit with hands over paper cutouts of family, car and home. Represents insurance."><div>Source: thodonal88 / Shutterstock.com</div></div>Reliance Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/reli-stock-quote/">RELI</a>) is a business group that acquires and manages retail insurance agencies in the United States. I chose to lead off the article with this stock specifically because it is not a pharma firm or another biotech stock. The purpose in doing so is not to say that <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> are bad. Instead, it is to show there are plenty of 10X <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> outside of the biotech sector.



As I mentioned, there is a lot of risk in investing in shares of stocks trading at these levels. Investing in Reliance Global will be no different. The stock has lost roughly 95% of its value over the last 12 months. It currently trades for 25 cents per share. That should logically raise a lot of red flags for investors. However, there are reasons to believe that the company can rebound from here. 



Primarily, the company recently announced a definitive agreement to acquire Spetner Associates. The integration of Spetner Associates is expected to double Reliance Global&rsquo;s annual revenues to $28 million.&nbsp;



That news was <a href="https://www.globenewswire.com/news-release/2024/05/15/2882429/0/en/Reliance-Global-Group-Announces-Game-Changing-Acquisition-of-Spetner-Associates-Projected-to-Double-Company-s-Revenue.html">announced on May 15</a> and sent share prices drastically higher. The bet at this time is the integration of the new partner will again significantly increase revenues. Despite the obvious risk, that&rsquo;s the clear narrative behind investing in Reliance Global.



<h2>aTyr Pharma (LIFE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>aTyr Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/life-stock-quote/">LIFE</a>) is a biotech stock focused on the treatment of lung diseases that lead to fibrosis, or scarring of the lung tissue.



It appears to be among the better biotech stocks to bet on at this time. The company&rsquo;s lead candidate drug, Efzofitimod, has received FDA and EU orphan drug designation. That effectively fast tracks its development for the treatment of sarcoidosis and scleroderma.



The company also has a deal in place with Japan&rsquo;s Kyorin Pharmaceutical worth up to $175 million To develop and commercialize Efzofitimod in Japan. The company&rsquo;s pipeline of drugs extends beyond Efzofitimod with that drug being the clear catalyst overall.&nbsp;



LIFE shares currently trade for $1.76 and <a href="https://stockanalysis.com/stocks/life/forecast/">have a consensus target price above $25</a>.&nbsp;



The company continues to release <a href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-second-positive-dsmb-review-efzofitimod">positive news about its lead candidate drug</a>. That is not the only good news surrounding aTyr Pharma. The company also announced inducement grants that allowed <a href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-4">two employees to purchase 9,400 shares of stock at $1.86</a>. That suggests there is an immediate upside in LIFE stock at the moment.



<h2>BioLineRx (BLRX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div>BioLineRx (NASDAQ:<a href="https://investorplace.com/stock-quotes/blrx-stock-quote/">BLRX</a>) is a company attempting to commercialize therapeutics for the treatment of various cancers and rare diseases including sickle cell disease. The company&rsquo;s recent announcements around those projects deserve particular attention and make the stock attractive.



BioLineRx truly does look like a biotech stock that&rsquo;s about to move much higher. Interested investors should read this <a href="https://www.prnewswire.com/news-releases/biolinerx-reports-first-quarter-2024-financial-results-and-recent-corporate-and-portfolio-updates-302156149.html">recent portfolio update from May 28</a>. The company&rsquo;s FDA-approved multiple myeloma treatment, Aphexda, is growing steadily in its first full quarter of post-approval adoption.&nbsp;



The drug is quickly making its way into the network of transplant centers and is placed at 26% of all institutions in the U.S. currently. BioLineRx expects that number to rise to 35% by the end of the second quarter and could rise to 60% by the end of the year.



The biotech is currently running at a slight net loss of $0.7 million but benefits from continued progress in clinical trials relating to other diseases including sickle cell disease. In short, there seem to be multiple reasons to bet on BLRX stock at the moment.



<h2>Knightscope (KSCP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/08/kscp1600-300x169.png" alt="Knightscope (KSCP) security robot patrols an outdoor parking lot"><div>Source: Michael Vi / Shutterstock.com</div></div>Knightscope (NASDAQ:<a href="https://investorplace.com/stock-quotes/kscp-stock-quote/">KSCP</a>) stock represents a company that builds fully autonomous security robots. Honestly, its products look a bit like something out of a dystopian future movie from the &rsquo;90s. Despite that, Knightscope&rsquo;s progress makes it very interesting for investors.



The company hasn&rsquo;t released highly detailed financial statements but the most recent indication that we have is from March. That report <a href="https://ir.knightscope.com/news-releases/news-release-details/knightscope-2023-estimated-revenues-increase-128-128-million">showed revenues increased by 128% to $12.8 million </a>during 2023. The report also includes some images of the company&rsquo;s AI-enabled security robots that are a bit cyberpunk and Robocop.&nbsp;



The company released another report days later updating the company&rsquo;s financial position. It showed that the company&rsquo;s net loss narrowed from $25.6 million to $22.1 million in 2023. It also noted the company has 10,000 machines in its network across the United States and the company plans to reduce its payroll expense by 30% this year.



The company has since <a href="https://ir.knightscope.com/news-and-events/news">won multiple contracts and deployed multiple tranches </a>of robots.&nbsp;



<h2>Adial Pharmaceuticals (ADIL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div>Adial Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/adil-stock-quote/">ADIL</a>) is a company working to address addiction disorders that are quite rampant across society. The reason to believe in the stock lies in its lead candidate drug, AD04. That drug is intended to treat alcohol use disorder, opioid use disorder and a host of potential other drug dependencies.&nbsp;



The company has identified a range of genetic phenotypes that respond to AD04. Adial Pharmaceuticals estimates that represents a $40 billion opportunity in the U.S. alone.



The company also secured patent rights protecting the ability of that drug to target specific gene sequences relating to various drug dependency disorders.&nbsp;



The company is clearly very interesting for its positioning relative to various substance dependencies and their overall socioeconomic burden. However, potential investors should also be aware the company&rsquo;s&nbsp;current liquidity only covers the company through the first quarter of 2025. Regardless, substance disorder pharmaceutical firms are a rapidly growing sub-sector within the industry and Adial Pharmaceuticals could certainly emerge as a winner.&nbsp;



<h2>Society Pass (SOPA)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/07/fintech_1600-300x169.jpg" alt='undervalued fintech stocks A concept image of a hand reaching toward the word "Fintech," which is surrounded by icons representing money and growth. Fintech Stock Bargains, fintech stock'><div>Source: Wright Studio / Shutterstock.com</div></div>Investors interested in the outsized growth prospects in Southeast Asia should take a look at Society Pass (NASDAQ:<a href="https://investorplace.com/stock-quotes/sopa-stock-quote/">SOPA</a>). The company continues to build an ecosystem encompassing e-commerce and fintech worth understanding at least.



The <a href="https://www.globenewswire.com/news-release/2023/12/07/2792494/0/en/Society-Pass-Inc-Nasdaq-SOPA-Ascendiant-Capital-Issues-3Q-2023-Equity-Research-Update-3Q-Results-Show-Solid-Revenue-Growth-and-Maintains-Positive-Outlook-on-Growth-Prospects.html">most recent earnings report</a> from the third quarter of 2023 shows that revenues grew by 11%. Clearly, that&rsquo;s not the sort of outsized growth many seek from emerging market opportunities. Nevertheless, there are things to like about Society Pass. What I like is that the company has zero debt and $8 million in cash.&nbsp;&nbsp;



Despite a net loss of $3.9 million in the period, the company managed to report a modest gross profit of $600,000. The company also has a $40 million line of credit should that ultimately be necessary. That line of credit is an indication institutional investors see the overall opportunity represented by Society Pass. Much like Adial Pharmaceutical, Society Pass is interesting for operating within a high-growth sub-sector that may not get as much attention as it deserves.



<h2>Enviva (EVA)</h2>



<div><img width="300" height="200" src="https://investorplace.com/wp-content/uploads/2022/01/carbon-dioxide-1600-300x200.png" alt="Environmental pollution, environmental problem, smoke from the chimney of an industrial plant or thermal power plant against a cloudy sky"><div>Source: AYDO8 / Shutterstock.com</div></div>Investing in Enviva (NYSE:<a href="https://investorplace.com/stock-quotes/eva-stock-quote/">EVA</a>) stock will appeal to green investors&nbsp;and industrial investors looking for turnaround opportunities. The company produces sustainable wood pellets intended to provide a low-carbon alternative to fossil fuels.



While the company has some interesting, promising catalysts, it is going through a transition as it attempts to affect a turnaround. The most recent earnings reports &mdash; from November 2023 &mdash; gets into those details.



Most of the report focused on the appointment of the company&rsquo;s previous CFO to an interim CEO position. He is essentially tasked with turning around deepening losses and righting the course for Enviva. The <a href="https://ir.envivabiomass.com/news/news-details/2023/Enviva-Reports-3Q-2023-Results/default.aspx">fundamentals tell the story of a company in trouble</a>. Revenues fell by a modest 1.3% in that report while net losses more than quadrupled to $85.2 million.&nbsp;



The company has <a href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0001592057/5aee415d-4604-4366-a34d-18c777395a61.pdf">not filed any subsequent financial reports</a> since November. It&rsquo;s clearly at risk of bankruptcy and restructuring. My sense is that the company&rsquo;s shares will trend downward but they certainly do <a href="https://stockanalysis.com/stocks/eva/forecast/">have the potential to 10X</a> nonetheless.&nbsp;



On Penny Stocks and Low-Volume Stocks:&nbsp;With only the rarest exceptions,&nbsp;InvestorPlace does not publish commentary about companies that have a market cap of&nbsp;less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because&nbsp;these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market&nbsp;manipulators. If we ever do publish commentary on a low-volume stock that may be&nbsp;affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this&nbsp;fact and warn readers of the risks.



Read More:&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a>



On the date of publication, Alex Sirois did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/millionaire-makers-7-stocks-you-can-buy-for-2-that-can-10x-by-2025/">Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025

The latest announcement is out from Society Pass (SOPA). Society Pass Incorporated witnessed a shift in its leadership as board members John Mackay...

Society Pass Leadership Overhaul and Board Expansion

Society Pass (SOPA) just unveiled an update. Jeremy Miller and Tan Bien Kiat have stepped down from their roles as directors of Society Pass Incorp...

Society Pass Announces Amicable Board Reshuffle

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic as we dive into all of the biggest news traders need to know about on Monday morning!



Moving stocks this morning are an acquisition deal, a strategic alliance, earnings data and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Tellurian (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tell-stock-quote/">TELL</a>) stock is rocketing more than 66% <a href="https://finance.yahoo.com/news/tellurian-acquired-woodside-approximately-900-222900949.html">due to a $900 million acquisition deal</a>.</li>



<li>Serve Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/serv-stock-quote/">SERV</a>) shares are soaring over 60% after Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>) <a href="https://investorplace.com/2024/07/serv-stock-soars-as-nvidia-reveals-big-bet-on-serve-robotics/">revealed a stake in the company</a>.</li>



<li>Castellum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ctm-stock-quote/">CTM</a>) stock is surging more than 56% after <a href="https://www.nasdaq.com/press-release/castellum-inc-announces-strategic-alliance-k2-2024-07-22">announcing a strategic alliance</a>.</li>



<li>Netcapital (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) shares are rising over 40% alongside heavy pre-market trading.</li>



<li>Richtech Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rr-stock-quote/">RR</a>) stock is increasing more than 27% after <a href="https://www.nasdaq.com/press-release/richtech-robotics-celebrates-completion-installation-adam-ghost-kitchens-inside">adding ADAM to certain ghost kitchens</a>.</li>



<li>CISO Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/ciso-stock-quote/">CISO</a>) shares are gaining over 24% after announcing <a href="https://www.nasdaq.com/press-release/ciso-global-announces-solution-mitigate-impact-crowdstrike-security-event-2024-07-19">a way to mitigate damage</a> from the CrowdStrike (NASDAQ:<a href="https://investorplace.com/stock-quotes/crwd-stock-quote/">CRWD</a>) issues last week.</li>



<li>Tellurian Inc. 8.25% Senior Notes due 2028 (NYSEMKT:<a href="https://investorplace.com/stock-quotes/telz-stock-quote/">TELZ</a>) are heading more than 21% higher this morning.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) stock is climbing over 18% without any clear news this morning.</li>



<li>Society Pass (NASDAQ:<a href="https://investorplace.com/stock-quotes/sopa-stock-quote/">SOPA</a>) shares are jumping more than 17% on Monday morning.</li>



<li>TuanChe (NASDAQ:<a href="https://investorplace.com/stock-quotes/tc-stock-quote/">TC</a>) stock is up over 16% without any clear news today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) stock is plummeting more than 24% after a major rally on Friday.</li>



<li>Sentage (NASDAQ:<a href="https://investorplace.com/stock-quotes/sntg-stock-quote/">SNTG</a>) shares are diving over 14% on Monday morning.</li>



<li>Sonoma Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/snoa-stock-quote/">SNOA</a>) stock is tumbling close to 14% this morning.</li>



<li>Novo Integrated Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvos-stock-quote/">NVOS</a>) shares are taking a nearly 14% beating after <a href="https://investorplace.com/earning-results/2024/07/nvos-stock-earnings-novo-integrated-sciences-for-q3-of-2024/">jumping Friday on earnings</a>.</li>



<li>Safe &amp; Green Development (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgd-stock-quote/">SGD</a>) stock is sliding over 13% on Monday morning.</li>



<li>Ryanair (NASDAQ:<a href="https://investorplace.com/stock-quotes/ryaay-stock-quote/">RYAAY</a>) shares are falling more than 13% alongside <a href="https://www.cnbc.com/2024/07/22/ryanair-q1-2024-results-shares-fall-on-lower-fares-fall-in-quarterly-profit.html">falling quarterly profit</a>.</li>



<li>Portage Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/">PRTG</a>) stock is dropping over 11% on Monday.</li>



<li>Stronghold Digital Mining (NASDAQ:<a href="https://investorplace.com/stock-quotes/sdig-stock-quote/">SDIG</a>) shares are decreasing more than 11% this morning.</li>



<li>60 Degrees (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtp-stock-quote/">SXTP</a>) stock is slipping over 10% on Monday morning.</li>



<li>PS International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares close out our pre-market stock movers down almost 10% on Monday.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-july-22nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Society Pass (NASDAQ:<a href="https://investorplace.com/stock-quotes/sopa-stock-quote/">SOPA</a>) just reported results for the second quarter of 2024.<ul><li>Society Pass reported earnings per share of -73 cents. This was above the analyst estimate for EPS of -83 cents.</li><li>The company reported revenue of $1.71 million.</li><li>This was 23.96% worse than the analyst estimate for revenue of $2.25 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/sopa-stock-earnings-society-pass-for-q2-of-2024/">SOPA Stock Earnings: Society Pass Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SOPA Stock Earnings: Society Pass Beats EPS, Misses Revenue for Q2 2024

Maxim Group analyst Allen Klee maintained a Hold rating on Society Pass (SOPA – Research Report) yesterday. The company's shares closed yesterday a...

Maxim Group Sticks to Its Hold Rating for Society Pass (SOPA)

ADIL

BLRX

CISO

LIFE

NUZE

NVDA

NVOS

RELI

SDIG

SNTG

SXTP

TELZ

Press Releases

Society Pass Inc. (Nasdaq: SOPA) 1Q 2024 Shareholder Update and Analyst Recommendations

Small Cap

Opinion

Thinking about buying stock in Certara, Stronghold Digital Mining, Society Pass, AgriFORCE Growing Systems, or Luxurban Hotels?

Financing

Society Pass Inc. Issues First Advance Notice to Strattners Bank, to Continue its Growth Plans

Society Pass Incorporated Announces 1-for-15 Reverse Split

Society Pass Set to Unlock and Monetize Current and Future Subsidiary Spin-Off Opportunities Through Strong and Flexible Financing

Society Pass Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Analyst Ratings

Ascendiant Capital publishes a company update on Society Pass (NASDAQ: SOPA), expecting strong growth over the next year

IPOs

Society Pass Inc. Bolstering Subsidiaries Ahead of IPOs to Drive Growth and Customer Engagement

Comments

Society Pass

Society Pass (SOPA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga